WEST PHARMACEUTICAL SERVICES INC (WST)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for WST
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WST | Retired Chief Executive Officer, ArQule, Inc. | 64 | ["Extensive global healthcare and biopharmaceutical experience","Chief Executive Officer of ArQule (2008–2020)","Executive roles at Bayer A.G. (2001–2008)","Expertise in strategic planning, capital allocation, and operational oversight","Experience in managing global pharmaceutical operations and regulatory affairs","Public company CEO and director of multiple international life-sciences companies"] | ["Audit Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REPL | Director | 65 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Pucci brings to the Board extensive global healthcare and biopharmaceutical experience through his leadership as Chief Executive Officer of ArQule (2008 2020) and his prior executive roles at Bayer A.G. (2001 2008). He guided ArQule, a biopharmaceutical oncology company, through its acquisition by Merck & Co., demonstrating strong strategic and governance expertise. Mr. Pucci offers deep insight into strategic planning, capital allocation and operational oversight. His experience managing global pharmaceutical operations and regulatory affairs strengthens the Board s governance, audit and risk oversight. Mr. Pucci s experience as a public company CEO and director of multiple international life-sciences companies supports his service on the Board s Audit Committee, where he contributes perspectives on enterprise risk and financial discipline. In addition to the directorships noted above, Mr. Pucci previously served on the Boards of Directors of Dyax, Inc. (acquired by Shire PLC in 2016), Algeta ASA (acquired by Bayer AG in 2014) and New Link Genetics Inc. In January 2025, he was appointed to be an independent Non-Executive Director to the Board of Directors of the Chiesi Group, a private global research-oriented biopharmaceutical company, where he also serves as Chairman of the Strategy/Sustainability/Innovation Committee.